Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

Menter Alan; Arenberger Petr; Balser Sigrid; Beissert Stefan; Cauthen Ashley; Czeloth Niklas; Soung Jennifer; Jazayeri Sasha; Weisenseel Peter; Jayadeva Girish

首页> 外文期刊>Expert opinion on biological therapy >Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

【24h】

Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

机译：生物仿真疾病BI 695501和AdalimalAb参考产物的类似疗效，安全性和免疫原性，中度至严重的慢性噬斑牛皮癣患者：随机阶段III伏尔师-PSO研究的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: BI 695501 is an approved biosimilar to Humira (R) reference product (RP).

机译：None

著录项

来源
《Expert opinion on biological therapy》 |2021年第6期|共10页
作者
Menter Alan; Arenberger Petr; Balser Sigrid; Beissert Stefan; Cauthen Ashley; Czeloth Niklas; Soung Jennifer; Jazayeri Sasha; Weisenseel Peter; Jayadeva Girish;
展开▼
作者单位

Baylor Scott &

White Inst Rehabil Dallas TX USA;

Univ Hosp Kralovske Vinohrady Dept Dermatol &

Venereol Prague Czech Republic;

Boehringer Ingelheim Pharma GmbH &

Co KG Biberach Germany;

Tech Univ Dresden Dept Dermatol Univ Klinikum Carl Gustav Carus Dresden Germany;

Renstar Med Res Ocala FL USA;

Boehringer Ingelheim Int GmbH Ingelheim Germany;

Southern Calif Dermatol Inc Santa Ana CA USA;

Alliance Dermatol &

Mohs Ctr PC Phoenix AZ USA;

TFS GmbH Hamburg Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
Adalimumab; BI 695501; biosimilar; equivalence; psoriasis;

机译：AdalimumAb;Bi 695501;生物仿制物;等价;牛皮癣;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis:a real-life cohort study [J] . Yan Zhao, Lin Cai, Xiao-Yang Liu, 中华医学杂志（英文版） . 2021,第011期
2. Phase 1 studies comparing safety,tolerability,pharmacokinetics and pharmacodynamics of HLX01(a rituximab biosimilar)to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma [J] . Yuankai Shi, Jifeng Feng, Xiaonan Hong, 中国癌症研究（英文版） . 2021,第003期
3. Study protocol of the Asian XELIRIrnProjecT (AXEPT): a multinational, randomized,rnnon‑inferiority, phase III trial of second‑linernchemotherapy for metastatic colorectal cancer,rncomparing the efficacy and safety of XELIRIrnwith or without bevacizumab versus FOLFIRIrnwith or without bevacizumab [J] . Masahito Kotaka, Hiroshi Matsumoto, Kentaro Yamazaki, 癌症（英文版） . 2016,第012期
4. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study [J] . Cohen Stanley B., Alonso-Ruiz Alberto, Klimiuk Piotr A., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第6期

机译：Adalimalab BioSimilar Bi 695501和Humira参考产物的类似疗效，安全性和免疫原性在患者中适度到严重活性的类风湿性关节炎：III期随机伏尔雷对等效研究的结果
5. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar Bl 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext) [J] . Stanley B. Cohen, Niklas Czeloth, Eric Lee, Expert opinion on biological therapy . 2019,第7a12期

机译：具有中度至严重活性的类风湿性关节炎的患者Adalimalab BioSimilar BL 695501和Adalimalab参考产物的长期安全性，疗效和免疫原性：来自第3B期扩展研究的结果（Voltaire-Reext）
6. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis [J] . Griffiths C. E. M., Thaci D., Gerdes S., British Journal of Dermatology . 2017,第4期

机译：Egality研究：验证，随机，双盲研究比较GP2015的疗效，安全性和免疫原性，提出的依赖替替尼替康BioSimilar，与中度至严重的慢性牙菌斑型牛皮癣患者的发起者产品
7. Study of Efficacy and Safety of Willow Bark Extract (Assalix) in Treatment of Chronic Low Back Pain in Patients of Different Age with Osteochondrosis [C] . V.V. Povoroznyuk, T.A. Karasevskaya International Pain Clinic Congress . 2008

机译：柳树皮提取物（Assalix）治疗不同年龄患者慢性低腰疼痛的疗效和安全性研究
8. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
9. Concise report: Similar efficacy safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study [O] . Stanley B Cohen, Alberto Alonso-Ruiz, Piotr A Klimiuk, -1

机译：简明报告：阿达木单抗BI 695501和Humira参考产品在中度至重度活动性类风湿关节炎患者中的相似功效安全性和免疫原性：来自VOLTAIRE-RA III期随机对照研究的结果
10. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study [O] . Alan Menter, Petr Arenberger, Sigrid Balser, 2020

机译：生物仿真效率的类似疗效，安全性和免疫原性，以及中度至严重的慢性牙菌斑牛皮癣患者中的Adalimalab参考产物：来自随机阶段III伏尔师-PSO研究的结果
11. Randomized Double-Blind Phase III Pivotal Field Trial of the Comparative Immunogenicity Safety and Tolerability of Two Yellow Fever 17D Vaccines (ARILVAX(Trademark) and YF-VAX(Trademark)) in Healthy Infants and Children in Peru [R] . Belmusto-Worn, V. E. , Sanchez, J. L. , McCarthy, K. , 2004

机译：秘鲁健康婴儿和儿童两种黄热病17D疫苗（aRILVaX（商标）和YF-VaX（商标））的比较免疫原性安全性和耐受性的随机双盲III期关键现场试验

Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

摘要

著录项

相似文献

相关主题

期刊订阅